尘埃落定| 捷迈邦美收购LDR
2016/6/8 麦迪睿

    

     来源：医栈

     作者：婉婷

    

     收 购

     捷迈邦美6月7日宣布以10亿美金收购LDR。作为收购的要约之一，捷迈邦美将以37美金/股收购LDR的发行股，相比昨日$22.58的收盘价，溢价率超64%。这一收购消息发出后，LDR股票当即暂停交易，并于今日美国东部时间早7:30恢复交易。据官方消息，该交易预期于今年三季度完成。对此，捷迈邦美表示，此次的收购对2017年的每股收益并不会有太多影响，但在之后会开始涨幅。至于2016年，相较FactSet consensus预估给出的7.99美金的每股股价，捷迈邦美承认每股收益预测将从7.85美金增至8.00美金。捷迈邦美首席执行官David Dvorak评论：“这是一次战略上互补的收购，引入LDR优秀的脊柱产品线，将大幅提升公司在骨科领域的创新影响力。”从今年年初至昨日，LDR的股价已下降10%，然而捷迈邦美股价回升18%，标普500指数上涨3.2%。

     Zimmer Biomet Holdings Inc. ZBH, -3.04% announced a deal Tuesday to buy medical device company LDR Holding Corp. LDRH, +63.37% in a deal valued at about $1 billion. As part of the deal, Zimmer will pay $37 a share for each LDR share outstanding, which represents a 64% premium to Monday's closing price of $22.58. LDR's stock is currently halted for news, and is set to resume trade at 7:30 a.m. ET. Zimmer said the deal, which is expected to close in the third quarter, should be neutral to adjusted earnings per share in 2017 and add to earnings after that. For 2016, Zimmer affirmed its adjusted EPS outlook of $7.85 to $8.00, compared with the FactSet consensus of $7.96. "This highly strategic and complementary transaction will enhance Zimmer Biomet's innovation leadership in musculoskeletal healthcare by adding a premier spine platform to our portfolio of solutions," said Zimmer Chief Executive David Dvorak. LDR's stock has dropped 10% year to date through Monday, while Zimmer's has rallied 18% and the S&P 500 has gained 3.2%.

     关于LDRLDR创立于法国Troyes，总部在美国德州的奥斯汀，是一家全球性医疗器械公司，专注于设计、商业化用于治疗脊柱病患者的新型、专利手术技术。LDR公司由Christophe Lavigne, Hervé Dinville 和Patrick Richard于2000年在法国特鲁瓦创立，公司专注为脊柱手术过程开发创新性技术。今天，所有LDR公司的资源都致力于高度专业化的骨科和神经外科市场。

     【本文为转载，麦迪睿不保证其准确性、可靠性、完整性，不对其观点负责。】

    

     【骨科医械联盟】——邀请您加入群聊

     长按识别二维码，加管理员后进入各省分会群

    

     长按指纹 > 识别图中二维码 > 添加管理员

    http://www.duyihua.cn
返回 麦迪睿 返回首页 返回百拇医药